Literature DB >> 29147802

Executive summary of the 12th HHT international scientific conference.

Jillian W Andrejecsk1, Anna E Hosman2, Luisa M Botella3, Claire L Shovlin4, Helen M Arthur5, Sophie Dupuis-Girod6, Elisabetta Buscarini7, Christopher C W Hughes1, Franck Lebrin8,9, Christine L Mummery10, Marco C Post11, Johannes J Mager2.   

Abstract

Hereditary hemorrhagic telangiectasia is an autosomal dominant trait affecting approximately 1 in 5000 people. A pathogenic DNA sequence variant in the ENG, ACVRL1 or SMAD4 genes, can be found in the majority of patients. The 12th International Scientific HHT Conference was held on June 8-11, 2017 in Dubrovnik, Croatia to present and discuss the latest scientific achievements, and was attended by over 200 scientific and clinical researchers. In total 174 abstracts were accepted of which 58 were selected for oral presentations. This article covers the basic science and clinical talks, and discussions from three theme-based workshops. We focus on significant emergent themes and unanswered questions. Understanding these topics and answering these questions will help to define the future of HHT research and therapeutics, and ultimately bring us closer to a cure.

Entities:  

Keywords:  Activin receptor-like kinase 1 (ALK1); Arteriovenous malformation; Endoglin; Epistaxis; HHT; Hereditary hemorrhagic telangiectasia

Mesh:

Substances:

Year:  2018        PMID: 29147802     DOI: 10.1007/s10456-017-9585-2

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  4 in total

1.  Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.

Authors:  Carolina Vázquez; María Laura Gonzalez; Augusto Ferraris; Juan Carlos Bandi; Marcelo Martín Serra
Journal:  PLoS One       Date:  2020-02-07       Impact factor: 3.240

2.  An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia.

Authors:  Haneen Sadick; Elena Schäfer; Christel Weiss; Nicole Rotter; Cornelia Emika Müller; Richard Birk; Maliha Sadick; Daniel Häussler
Journal:  Exp Ther Med       Date:  2022-07-05       Impact factor: 2.751

Review 3.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

Authors:  Veronique M M Vorselaars; Anna E Hosman; Cornelis J J Westermann; Repke J Snijder; Johannes J Mager; Marie-Jose Goumans; Marco C Post
Journal:  Int J Mol Sci       Date:  2018-10-17       Impact factor: 5.923

4.  Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia.

Authors:  Patricia P Bloom; Josanna Rodriguez-Lopez; Alison S Witkin; Hanny Al-Samkari; David J Kuter; Amirkasra Mojtahed; Jay Luther
Journal:  Clin Transl Gastroenterol       Date:  2020-01       Impact factor: 4.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.